Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 4 | 2022 | 61 | 1.270 |
Why?
|
| Hot Flashes | 2 | 2015 | 8 | 1.010 |
Why?
|
| Reproductive Medicine | 1 | 2021 | 2 | 0.820 |
Why?
|
| Leiomyoma | 5 | 2013 | 28 | 0.790 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 269 | 0.650 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 427 | 0.600 |
Why?
|
| Sweating | 1 | 2015 | 19 | 0.520 |
Why?
|
| Acupuncture | 1 | 2014 | 1 | 0.490 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2014 | 11 | 0.480 |
Why?
|
| Minority Health | 1 | 2013 | 11 | 0.470 |
Why?
|
| Cost of Illness | 1 | 2013 | 132 | 0.440 |
Why?
|
| Health Status Disparities | 2 | 2022 | 219 | 0.430 |
Why?
|
| Quality of Life | 2 | 2022 | 920 | 0.340 |
Why?
|
| Uterine Neoplasms | 4 | 2010 | 63 | 0.310 |
Why?
|
| Mentors | 1 | 2021 | 55 | 0.190 |
Why?
|
| Ovulation Induction | 2 | 1997 | 14 | 0.180 |
Why?
|
| Catechin | 2 | 2010 | 30 | 0.180 |
Why?
|
| Mental Health | 1 | 2022 | 244 | 0.180 |
Why?
|
| Quality of Health Care | 1 | 2021 | 219 | 0.180 |
Why?
|
| Female | 13 | 2022 | 28410 | 0.170 |
Why?
|
| Health Personnel | 1 | 2021 | 244 | 0.160 |
Why?
|
| Humans | 15 | 2022 | 54205 | 0.160 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2015 | 5 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1096 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 41 | 0.130 |
Why?
|
| Societies, Medical | 2 | 2015 | 194 | 0.130 |
Why?
|
| Blood Platelets | 1 | 1997 | 269 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 27 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 28 | 0.120 |
Why?
|
| Ovary | 1 | 2013 | 105 | 0.110 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2012 | 9 | 0.110 |
Why?
|
| Research Report | 1 | 2012 | 16 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 53 | 0.110 |
Why?
|
| Vitamin D | 1 | 2013 | 101 | 0.110 |
Why?
|
| Estrogens | 1 | 2013 | 244 | 0.100 |
Why?
|
| Algorithms | 1 | 2015 | 697 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 35 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2013 | 293 | 0.090 |
Why?
|
| Goserelin | 1 | 2007 | 2 | 0.080 |
Why?
|
| Ferrous Compounds | 1 | 2007 | 11 | 0.080 |
Why?
|
| Premedication | 1 | 2007 | 18 | 0.080 |
Why?
|
| Hematinics | 1 | 2007 | 18 | 0.080 |
Why?
|
| Antioxidants | 1 | 2010 | 297 | 0.080 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2007 | 24 | 0.080 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2007 | 31 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 49 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 476 | 0.070 |
Why?
|
| Apoptosis | 2 | 2010 | 1300 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 1202 | 0.060 |
Why?
|
| Estradiol | 2 | 1997 | 219 | 0.060 |
Why?
|
| Biology | 1 | 2022 | 9 | 0.050 |
Why?
|
| Washington | 1 | 2022 | 46 | 0.050 |
Why?
|
| United States | 1 | 2013 | 5196 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2010 | 15 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2010 | 82 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2003 | 574 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2010 | 477 | 0.040 |
Why?
|
| Middle Aged | 1 | 2013 | 13072 | 0.040 |
Why?
|
| Adenosine Diphosphate | 1 | 1997 | 23 | 0.040 |
Why?
|
| Arachidonic Acid | 1 | 1997 | 39 | 0.040 |
Why?
|
| Fertilization in Vitro | 1 | 1997 | 36 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 1997 | 53 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 1997 | 82 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 1997 | 242 | 0.030 |
Why?
|
| Collagen | 1 | 1997 | 223 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 1993 | 69 | 0.030 |
Why?
|
| Decision Making | 1 | 2015 | 286 | 0.030 |
Why?
|
| Time Factors | 2 | 2009 | 3209 | 0.030 |
Why?
|
| Camellia sinensis | 1 | 2009 | 7 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 73 | 0.020 |
Why?
|
| Tea | 1 | 2009 | 35 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 283 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5604 | 0.020 |
Why?
|
| Adult | 3 | 2007 | 14191 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 158 | 0.020 |
Why?
|
| Premenopause | 1 | 2007 | 26 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 58 | 0.020 |
Why?
|
| North America | 1 | 2007 | 68 | 0.020 |
Why?
|
| Plant Extracts | 1 | 2009 | 193 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 126 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 459 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 426 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1476 | 0.020 |
Why?
|
| Animals | 2 | 2013 | 14384 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2007 | 741 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2009 | 1753 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 531 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1202 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 6413 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1993 | 8 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1993 | 9 | 0.010 |
Why?
|
| Antithrombin III | 1 | 1993 | 13 | 0.010 |
Why?
|
| Thrombin | 1 | 1993 | 49 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1993 | 124 | 0.010 |
Why?
|
| Male | 1 | 2012 | 27311 | 0.010 |
Why?
|